Recent News

• 11.10.2025 - Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.10.2025 - Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.04.2025 - Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
• 11.04.2025 - Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
• 10.27.2025 - Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
• 10.27.2025 - Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
• 10.14.2025 - Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
• 10.14.2025 - Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
• 10.09.2025 - Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
• 10.09.2025 - Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

Recent Filings

• 11.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.29.2025 - EX-99.1 EX-99.1
• 10.29.2025 - 8-K Current report
• 10.27.2025 - 8-K Current report
• 10.27.2025 - EX-99.1 EX-99.1
• 10.15.2025 - 3 Initial statement of beneficial ownership of securities
• 10.15.2025 - 4 Statement of changes in beneficial ownership of securities